Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.
7 papers
This observational study followed 98 people who microdosed psychedelics over six weeks and found that people reported better psychological functioning on days they took a microdose, but there was little evidence that those effects lasted into the next days. Among 63 people who completed formal tests before and after the…
This paper reviews research on using psychedelic drugs to treat addiction. The authors say scientific and medical interest has grown a lot in the last ten years and that early evidence is starting to show these treatments can be safe and may help with psychiatric problems including addiction. The review…
This review and meta-analysis looked at studies up to 2024 on body-positive social media content. It reviewed 56 studies (19 were left out of the meta-analysis for bad or missing data). Overall, short-term exposure to body-positive posts was linked to better body satisfaction and improved mood, especially when posts showed…
Researchers followed people who chose to take a psychedelic on their own and filled out online surveys before, and two and four weeks after, the experience. About 430 adolescents aged 16 to 24 and about 650 adults aged 25 and older were included. Adolescents showed a measurable improvement in mental…
Researchers followed about 22,000 US adults aged 18 to 50 across a two-month period to see whether real-world psychedelic use was linked with changes in psychotic or manic symptoms. About 12,300 people finished the follow-up and about 500 reported using psychedelics during the study. The main finding was that psychedelic…
This study pooled data from 19 observational studies with 17,746 adolescents and young adults (ages 10–25) to measure how resilience and mental health are related. The authors found that higher resilience was linked to fewer negative mental-health signs (correlation r = -0.391) and to stronger positive mental-health outcomes (r =…
Researchers followed people with treatment-resistant major depressive disorder for 52 weeks after a single dose of a pharmaceutical psilocybin (COMP360). In the original randomized trial (COMP001, n=233), the median time until a prespecified depressive event was 92 days for the 25 mg group, 83 days for the 10 mg group,…
